Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.5266
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ONCT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.5266
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$1.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.58M
KGV:
0.00
EPS:
-11.69
Netto-Cashflow:
$-26.63M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$9.88
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Firmenname
Oncternal Therapeutics Inc
Sektor
Branche
Telefon
(858) 434-1113
Adresse
12230 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie ONCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCT
Oncternal Therapeutics Inc
|
0.00 | 1.56M | 0 | -34.58M | -26.63M | -11.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-23 | Eingeleitet | Northland Capital | Outperform |
Oncternal Therapeutics Inc Aktie (ONCT) Neueste Nachrichten
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - The AM Reporter
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Metastatic Prostate Cancer Market Future Business - openPR.com
Chronic Lymphocytic Leukemia Pipeline Analysis and Clinical - openPR.com
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewswire
From Nasdaq to Dark: What's Next for Oncternal After March 2025 Delisting? - StockTitan
B-Cell Non-Hodgkin Lymphoma Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Ewing Sarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
3 Top Tech Stocks to Buy Right Now - The Globe and Mail
Oncternal Therapeutics (ONCT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, - openPR
Billionaire Investor David Tepper Doubles Down on These Stocks. Should You Follow? - The Globe and Mail
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Metastatic Prostate Cancer Clinical and Non-Clinical Studies, - openPR
Head-To-Head Survey: Oncternal Therapeutics (NASDAQ:ONCT) & Organigram (NASDAQ:OGI) - Defense World
Future-Proofing Growth of Metastatic Prostate Cancer Market, - openPR
IBM Stock 2025 Outlook: Can AI and Cloud Revive IBM’s Growth? - The Globe and Mail
StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
B-cell Lymphoma Pipeline Update 2024: FDA Approvals, - openPR
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Marketscreener.com
CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan
ONCT stock touches 52-week low at $0.61 amid market challenges - Investing.com Australia
ONCT stock touches 52-week low at $0.61 amid market challenges By Investing.com - Investing.com South Africa
ONCT stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
ONCT stock touches 52-week low at $0.83 amid market challenges - Investing.com
Oncternal shares to be delisted from Nasdaq - Investing.com
Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks
ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com
Oncternal announces workforce reduction, executive changes - Investing.com
Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks
ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com
Finanzdaten der Oncternal Therapeutics Inc-Aktie (ONCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):